Human parathyroid peptide treatment of vertebral osteoporosis.
Previous studies have shown that treatment with daily injections of human parathyroid peptide (hPTH) 1-34 increase axial cancellous bone mass partially at the expense of peripheral cortical bone. In the present work the same hPTH 1-34 regime given for 12 months has been combined with oestrogen or na...
Egile Nagusiak: | Reeve, J, Arlot, M, Bradbeer, J, Hesp, R, Mcally, E, Meunier, P, Zanelli, J |
---|---|
Formatua: | Journal article |
Hizkuntza: | English |
Argitaratua: |
Springer-Verlag
1993
|
Antzeko izenburuak
-
Treatment of osteoporosis with parathyroid peptide (hPTH 1-34) and oestrogen: increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone.
nork: Bradbeer, J, et al.
Argitaratua: (1992) -
Temporal variations in iliac trabecular bone formation in vertebral osteoporosis.
nork: Arlot, M, et al.
Argitaratua: (1993) -
Periodic courses of human 1-34 parathyroid peptide alternating with calcitriol paradoxically reduce bone remodelling in spinal osteoporosis.
nork: Reeve, J, et al.
Argitaratua: (1987) -
A short-cycle ADFR regimen using parathyroid peptide hPTH 1–34 in idiopathic osteoporosis
nork: Reeve, J, et al.
Argitaratua: (1986) -
Iliac trabecular bone formation predicts radial trabecular bone density changes in type 1 osteoporosis.
nork: Hesp, R, et al.
Argitaratua: (1991)